Bonesupport successfully completed its IPO and started trading on Nasdaq Stockholm on 21 June. The final price in the offering was SEK 29 per share. In total 17,241,379 new shares in Bonesupport are issued in the offering. The transaction was heavily oversubscribed with highly concentrated allocation and attracted strong interest among Swedish and international investors.
Bonesupport is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bioceramic bone graft substitutes that remodel to the patient`s own bone and have the capability of eluting drugs directly into the bone void. Bonesupport`s marketed synthetic bone graft substitutes are all based on the Company`s novel and proprietary technology platform